TAS-102 Extends Overall Survival in Refractory Metastatic Colorectal Cancer
Results of the RECOURSE trial may make the combination agent a new standard of care in advanced disease.
Results of the RECOURSE trial may make the combination agent a new standard of care in advanced disease.
Inaccurate test results falsely classify some women as HER2 negative, denying them the benefits of targeted treatment.
A study that included almost half a million mammograms suggests that tomosynthesis combined with digital mammography may become the new standard of care.
For the first time, systemically administered virotherapy has been used to treat disseminated cancer.
Ipilimumab significantly reduced the risk of melanoma recurrence after resection, but drug toxicity will limit its use.
New techniques for detecting prostate cancer are finding disease more often and call into question the criteria for active surveillance.
A prospective survey found no reduction in cancer incidence in women eating organic food, but there’s more to the story.
Antiangiogenic cancer therapies elevate blood pressure in almost all patients, and put some at risk for stroke and myocardial infarction.
Use of a cost-effective treatment is declining steadily while more expensive therapies grow in popularity.
Inflammation and prostate cancer appear to be linked, but a causative connection has not yet been proven.